we will not know even with these there mayson trials, be weird side effects we don't detect in these initial trials. all of these things are true when we're licensing vaccines and other contacts, but it will be true here also. i actually think that this is a sort of national, teachable moment about vaccines. in thebsolutely -- i saw chat box, somebody mentioning the "new york times" vaccine tracker. i would really encourage anyone listening who has not gone to that website and who has not looked at that vaccine tracker to look at it, because it's an extraordinary peefs education for the general public about the kinds of vaccines that we're evaluating. but i think it's also really important when we do efficacy trials for the public to begin to understand, and explained in ways that everyone can understand, quite frankly what , did some of the statistical tests that we do? when a lower bounce by 30%, what does that actually mean, and what does the point estimate mean? and if we say something, you 70%, one vaccine is effective, and one is 65% effective against the endpoints, and the con